Intobac Eye Drops(Tobramycin)

Therapeutic Group: Ophthalmic

Presentation

Intobac 0.3% eye drops: Each ml contains Tobramycin USP 3 mg.

Description

Intobac is a broad-spectrum, aminoglycoside antibiotic of bacteriocidal type of action.

It works by inhibition of bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome.

Indications

Intobac eye drops is a topical antibiotic indicated in treatment of external bacterial infections of the eye and its adnexa caused by susceptible organisms:

Gram-positive microorganisms:

Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae,

Streptococcus sp. of group A beta-hemolytic and some nonhemolytic species.

Gram-negative microorganisms:

Escherichia coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Klebsiella sp., Proteus mirabillis, Proteus vulgaris, Haemophilus influenzae, Morganella morganii, some strains of Neisseria, Acinetobacter calcoaceticus, Providentia, Serratia, Salmonella sp.

Dosage & Administration

Adults: If the infection is mild to moderate, 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, 2 drops into the eye(s) every hour until there is improvement ,following which treatment should be reduced prior to discontinuation.
Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

Side Effects

Localized ocular toxicity and hypersensitivity, including lid itching and swelling, conjunctival erythema and lacrimation

Precautions

Sensitivity to topically applied aminoglycosides may occur in some patients. If a sensitivity reaction to tobramycin occurs, discontinue use. Prolonged use may lead to skin sensitisation or result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs appropriate therapy should be initiated

Use in Pregnancy & Lactation

Pregnancy Category B. Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.